I'd like to add separately that having Steve here,
Post# of 7769
It is rare to find a stock that bears such a clear imprinting of having the DNA (the genetic material) to work well in the long term. The more I sift through at the opportunities to be taken in China by Scrips, with its uniquely suitable profile for that market, the better it looks.
The figures you give for revenues in your third paragraph would translate into a really strong position for SCRC worldwide, and an ability to build out into many other countries, including Japan and Indonesia..